URGN
NASDAQUroGen Pharma Ltd.
News · 26 weeks49+125%
2026-03-012026-08-23
Mix2790d
- Insider11(41%)
- Other9(33%)
- SEC Filings5(19%)
- Earnings2(7%)
Latest news
25 items- INSIDERChief Medical Officer Schoenberg Mark sold $2,854,853 worth of ordinary shares (60,677 units at $47.05), decreasing direct ownership by 51% to 59,086 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- PRIntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology TherapiesIntraGel secures up to $7 million equity investment from UroGen® to advance the Phase 2 clinical study of TumoCure, for the treatment of advanced head and neck cancerUroGen gains access to IntraGel's biodegradable sustained-release gel platform with broad potential across solid tumors, as well as an exclusive option to acquire worldwide rights to TumoCureNAZARETH, Israel, Aug. 20, 2026 /PRNewswire/ -- IntraGel Therapeutics, developer of next generation long-acting injectables, today announced an equity investment agreement and a strategic Option and Research License Agreement (the Option Agreement) with UroGen Pharma Ltd. (NASDAQ:URGN), a biotechnology company dedicated to developing and com
- SECUroGen Pharma Ltd. filed SEC Form 8-K: Other Events8-K - UroGen Pharma Ltd. (0001668243) (Filer)
- PRUroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology PipelineCollaboration grants UroGen a research license and exclusive options to license and develop up to three oncology products utilizing IntraGel's proprietary SRGel platformAgreement also includes an exclusive option to acquire worldwide rights to TumoCure, an investigational therapy for advanced head and neck cancer PRINCETON, N.J., Aug. 20, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced a strategic Option and Research License Agreement (the Option Agreement) and a related equity investment agreement (the Investment Agreement) wit
- PRUroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBCPRINCETON, N.J., Aug. 17, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational drug UGN-103 (mitomycin) for intravesical solution. UGN-103 is a next-generation mitomycin formulation being developed for the treatment of adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). It is built on the clinical and commercial foundation of ZUSDURI (mitomycin) for intravesical solution. "The N
- SECAmendment: SEC Form SCHEDULE 13G/A filed by UroGen Pharma Ltd.SCHEDULE 13G/A - UroGen Pharma Ltd. (0001668243) (Subject)
- SECSEC Form 10-Q filed by UroGen Pharma Ltd.10-Q - UroGen Pharma Ltd. (0001668243) (Filer)
- SECUroGen Pharma Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - UroGen Pharma Ltd. (0001668243) (Filer)
- PRUroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and HighlightsZUSDURI® generated $50.4 million in revenue in the second quarter of 2026, representing 73% quarter-over-quarter growthOnce issued, new U.S. patent is expected to provide protection into July 2044 for ZUSDURI and UGN-103Continued advancement of pipeline, with UGN-103 on track for NDA submission in the third quarter of 2026 and UGN-501 expected to begin a Phase 1 trial in the fourth quarter of 2026Conference call and webcast held today at 10:00 AM ET PRINCETON, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial resu
- PRUroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026PRINCETON, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report second quarter 2026 financial results on Wednesday, August 5th, 2026, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. A live public webcast of the earnings conference call can be accessed on UroGen’s Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days. About UroGen Pharma Ltd. UroG
- PRUroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103PRINCETON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application no. 18/784,354 entitled "Treatment of Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer With a Thermally Gelling Pharmaceutical Composition Containing Mitomycin." The allowed claims cover methods of treating patients with recurrent, low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) without a transurethral resect
- INSIDERChief Medical Officer Schoenberg Mark sold $400,000 worth of Ordinary Shares (10,000 units at $40.00) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 119,763 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- PRUroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder CancerFDA clearance enables initiation of a planned Phase 1 clinical study evaluating local intravesical administration of UGN-501, with patient enrollment expected to begin in Q4 2026UGN-501 is a differentiated investigational next-generation oncolytic virus designed to combine direct tumor cell destruction with anti-tumor immune activation PRINCETON, N.J., July 08, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the U.S. Food and Drug Administration (FDA) cleared the Company's Investigational New Drug application (IND) for UGN-501, a
- INSIDERChief Medical Officer Schoenberg Mark sold $350,100 worth of Ordinary Shares (10,000 units at $35.01) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 129,763 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- INSIDERSEC Form 4 filed by Director Wildman Daniel George4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- INSIDERSEC Form 4 filed by Director Robinson James A. Jr.4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- INSIDERSEC Form 4 filed by Director Holden Stuart4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- INSIDERSEC Form 4 filed by Director Butitta Cynthia M4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- INSIDERSEC Form 4 filed by Director Wen Leana4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- INSIDERSEC Form 4 filed by Director Belldegrun Arie4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SECUroGen Pharma Ltd. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - UroGen Pharma Ltd. (0001668243) (Filer)
- INSIDERChief Medical Officer Schoenberg Mark converted options into 10,000 units of Ordinary Shares and sold $142,561 worth of Ordinary Shares (5,222 units at $27.30), increasing direct ownership by 4% to 139,763 units (SEC Form 4) (for withholding tax)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- PRUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PRINCETON, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units ("RSUs") to 21 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of JELMYTO® (mitomycin) for pyelocalyceal solution and ZUSDURITM (mitomycin) for intravesical solution, UroGen's only approved products, and the continued development of UroGen's pipeline. Up to 102,700 ordinary shares of UroGen are issuable upon the vesting and settlement of
- SECUroGen Pharma Ltd. filed SEC Form 8-K: Other Events8-K - UroGen Pharma Ltd. (0001668243) (Filer)
- PRUroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solutionAgreement reinforces the value of UroGen's innovation and reflects the strength of the Company's intellectual property portfolioTeva will be granted a non-exclusive license to sell its generic version of JELMYTO beginning on September 15, 2030, if approved by the FDA PRINCETON, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has entered into a settlement and license agreement (the "Agreement"') with Teva Pharmaceuticals, Inc. and Teva Pharmaceuticals, USA, Inc. (collectively, "Teva"). This Agreement resolve
URGN FAQ
7 questionsWhat does UroGen Pharma Ltd. do?
UroGen Pharma Ltd., a biopharmaceutical company, engages in the development and commercialization novel solutions for specialty cancers and urologic diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer...Where does URGN stock trade?
UroGen Pharma Ltd. (URGN) is listed on NASDAQ.What sector and industry is URGN in?
UroGen Pharma Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did UroGen Pharma Ltd. go public?
UroGen Pharma Ltd. (URGN) completed its IPO in 2017.What are analysts saying about URGN?
UroGen Pharma Ltd. has had 8 recent analyst actions on file. The most recent action was from Ladenburg Thalmann: Buy with a $4300.00 price target on 2026-05-11. Recent price targets range from $2300.00 to $4300.00.What companies are similar to URGN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare URGN side-by-side with any of them on Quantisnow.How can I track URGN on Quantisnow?
Quantisnow aggregates UroGen Pharma Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow URGN to receive live email and push alerts on every new disclosure.